Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA

Jim Ackland, Susan Allen, Daniel Barth-Jones, Deborah Birx, Elwyn Chomba, Gavin Churchyard, Ann Duerr, Shuigao Jin, Margaret Johnston, Patricia E. Fast, Alan Fix, Mary Foulkes, Dean Follmann, Raymond Hutubessy, Siobhan Malone, Ronald Gray, Abhay Indrayan, Jonathan Levin, Bonnie J. Mathieson, Timothy D. MastroJohn McNeil, Saladin Osmanov, Punnee Pitisuttithum, Barry Peters, Etienne Karita, Michael N. Robertson, R. Ramakrishnan, Helen Rees, Wasima Rida, Yuhua Ruan, Eric Sandström, Claudia Schmidt, Peter Smith, Steven Self, Georges Thiry, Judith Wasserheit, Frances Priddy, Ibou Thior, Mitchell Warren, David Cooper, Pontiano Kaleebu, Ruth Macklin, Godfrey Tangwa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This report summarizes the discussions and recommendations from a consultation held in New York City, USA (31 January-2 February 2006) organized by the joint World Health Organization-United Nations Programme on HIV/AIDS HIV Vaccine Initiative and the International AIDS Vaccine Initiative. The consultation discussed issues related to the design and implementation of phase IIB 'test of concept' trials (phase IIB-TOC), also referred to as 'proof of concept' trials, in evaluating candidate HIV vaccines and their implications for future approval and licensure. The results of a single phase IIB-TOC trial would not be expected to provide sufficient evidence of safety or efficacy required for licensure. In many instances, phase IIB-TOC trials may be undertaken relatively early in development, before manufacturing processes and capacity are developed sufficiently to distribute the vaccine on a large scale. However, experts at this meeting considered the pressure that could arise, particularly in regions hardest hit by AIDS, if a phase IIB-TOC trial showed high levels of efficacy. The group largely agreed that full-scale phase III trials would still be necessary to demonstrate that the vaccine candidate was safe and effective, but emphasized that governments and organizations conducting trials should consider these issues in advance. The recommendations from this meeting should be helpful for all organizations involved in HIV vaccine trials, in particular for the national regulatory authorities in assessing the utility of phase IIB-TOC trials in the overall HIV vaccine research and development process.

Original languageEnglish (US)
Pages (from-to)539-546
Number of pages8
JournalAIDS
Volume21
Issue number4
DOIs
StatePublished - Feb 2007

Fingerprint

AIDS Vaccines
Referral and Consultation
Licensure
Vaccines
Organizations
United Nations
Acquired Immunodeficiency Syndrome
Joints
HIV
Safety
Pressure
Research

Keywords

  • Clinical trial design
  • HIV vaccines
  • Phase IIB trials
  • Proof of concept trials
  • Test of concept trials
  • Vaccine efficacy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. / Ackland, Jim; Allen, Susan; Barth-Jones, Daniel; Birx, Deborah; Chomba, Elwyn; Churchyard, Gavin; Duerr, Ann; Jin, Shuigao; Johnston, Margaret; Fast, Patricia E.; Fix, Alan; Foulkes, Mary; Follmann, Dean; Hutubessy, Raymond; Malone, Siobhan; Gray, Ronald; Indrayan, Abhay; Levin, Jonathan; Mathieson, Bonnie J.; Mastro, Timothy D.; McNeil, John; Osmanov, Saladin; Pitisuttithum, Punnee; Peters, Barry; Karita, Etienne; Robertson, Michael N.; Ramakrishnan, R.; Rees, Helen; Rida, Wasima; Ruan, Yuhua; Sandström, Eric; Schmidt, Claudia; Smith, Peter; Self, Steven; Thiry, Georges; Wasserheit, Judith; Priddy, Frances; Thior, Ibou; Warren, Mitchell; Cooper, David; Kaleebu, Pontiano; Macklin, Ruth; Tangwa, Godfrey.

In: AIDS, Vol. 21, No. 4, 02.2007, p. 539-546.

Research output: Contribution to journalArticle

Ackland, J, Allen, S, Barth-Jones, D, Birx, D, Chomba, E, Churchyard, G, Duerr, A, Jin, S, Johnston, M, Fast, PE, Fix, A, Foulkes, M, Follmann, D, Hutubessy, R, Malone, S, Gray, R, Indrayan, A, Levin, J, Mathieson, BJ, Mastro, TD, McNeil, J, Osmanov, S, Pitisuttithum, P, Peters, B, Karita, E, Robertson, MN, Ramakrishnan, R, Rees, H, Rida, W, Ruan, Y, Sandström, E, Schmidt, C, Smith, P, Self, S, Thiry, G, Wasserheit, J, Priddy, F, Thior, I, Warren, M, Cooper, D, Kaleebu, P, Macklin, R & Tangwa, G 2007, 'Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA', AIDS, vol. 21, no. 4, pp. 539-546. https://doi.org/10.1097/QAD.0b013e328011a0c9
Ackland, Jim ; Allen, Susan ; Barth-Jones, Daniel ; Birx, Deborah ; Chomba, Elwyn ; Churchyard, Gavin ; Duerr, Ann ; Jin, Shuigao ; Johnston, Margaret ; Fast, Patricia E. ; Fix, Alan ; Foulkes, Mary ; Follmann, Dean ; Hutubessy, Raymond ; Malone, Siobhan ; Gray, Ronald ; Indrayan, Abhay ; Levin, Jonathan ; Mathieson, Bonnie J. ; Mastro, Timothy D. ; McNeil, John ; Osmanov, Saladin ; Pitisuttithum, Punnee ; Peters, Barry ; Karita, Etienne ; Robertson, Michael N. ; Ramakrishnan, R. ; Rees, Helen ; Rida, Wasima ; Ruan, Yuhua ; Sandström, Eric ; Schmidt, Claudia ; Smith, Peter ; Self, Steven ; Thiry, Georges ; Wasserheit, Judith ; Priddy, Frances ; Thior, Ibou ; Warren, Mitchell ; Cooper, David ; Kaleebu, Pontiano ; Macklin, Ruth ; Tangwa, Godfrey. / Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. In: AIDS. 2007 ; Vol. 21, No. 4. pp. 539-546.
@article{7afa339086c44b809892579712279ee4,
title = "Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA",
abstract = "This report summarizes the discussions and recommendations from a consultation held in New York City, USA (31 January-2 February 2006) organized by the joint World Health Organization-United Nations Programme on HIV/AIDS HIV Vaccine Initiative and the International AIDS Vaccine Initiative. The consultation discussed issues related to the design and implementation of phase IIB 'test of concept' trials (phase IIB-TOC), also referred to as 'proof of concept' trials, in evaluating candidate HIV vaccines and their implications for future approval and licensure. The results of a single phase IIB-TOC trial would not be expected to provide sufficient evidence of safety or efficacy required for licensure. In many instances, phase IIB-TOC trials may be undertaken relatively early in development, before manufacturing processes and capacity are developed sufficiently to distribute the vaccine on a large scale. However, experts at this meeting considered the pressure that could arise, particularly in regions hardest hit by AIDS, if a phase IIB-TOC trial showed high levels of efficacy. The group largely agreed that full-scale phase III trials would still be necessary to demonstrate that the vaccine candidate was safe and effective, but emphasized that governments and organizations conducting trials should consider these issues in advance. The recommendations from this meeting should be helpful for all organizations involved in HIV vaccine trials, in particular for the national regulatory authorities in assessing the utility of phase IIB-TOC trials in the overall HIV vaccine research and development process.",
keywords = "Clinical trial design, HIV vaccines, Phase IIB trials, Proof of concept trials, Test of concept trials, Vaccine efficacy",
author = "Jim Ackland and Susan Allen and Daniel Barth-Jones and Deborah Birx and Elwyn Chomba and Gavin Churchyard and Ann Duerr and Shuigao Jin and Margaret Johnston and Fast, {Patricia E.} and Alan Fix and Mary Foulkes and Dean Follmann and Raymond Hutubessy and Siobhan Malone and Ronald Gray and Abhay Indrayan and Jonathan Levin and Mathieson, {Bonnie J.} and Mastro, {Timothy D.} and John McNeil and Saladin Osmanov and Punnee Pitisuttithum and Barry Peters and Etienne Karita and Robertson, {Michael N.} and R. Ramakrishnan and Helen Rees and Wasima Rida and Yuhua Ruan and Eric Sandstr{\"o}m and Claudia Schmidt and Peter Smith and Steven Self and Georges Thiry and Judith Wasserheit and Frances Priddy and Ibou Thior and Mitchell Warren and David Cooper and Pontiano Kaleebu and Ruth Macklin and Godfrey Tangwa",
year = "2007",
month = "2",
doi = "10.1097/QAD.0b013e328011a0c9",
language = "English (US)",
volume = "21",
pages = "539--546",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA

AU - Ackland, Jim

AU - Allen, Susan

AU - Barth-Jones, Daniel

AU - Birx, Deborah

AU - Chomba, Elwyn

AU - Churchyard, Gavin

AU - Duerr, Ann

AU - Jin, Shuigao

AU - Johnston, Margaret

AU - Fast, Patricia E.

AU - Fix, Alan

AU - Foulkes, Mary

AU - Follmann, Dean

AU - Hutubessy, Raymond

AU - Malone, Siobhan

AU - Gray, Ronald

AU - Indrayan, Abhay

AU - Levin, Jonathan

AU - Mathieson, Bonnie J.

AU - Mastro, Timothy D.

AU - McNeil, John

AU - Osmanov, Saladin

AU - Pitisuttithum, Punnee

AU - Peters, Barry

AU - Karita, Etienne

AU - Robertson, Michael N.

AU - Ramakrishnan, R.

AU - Rees, Helen

AU - Rida, Wasima

AU - Ruan, Yuhua

AU - Sandström, Eric

AU - Schmidt, Claudia

AU - Smith, Peter

AU - Self, Steven

AU - Thiry, Georges

AU - Wasserheit, Judith

AU - Priddy, Frances

AU - Thior, Ibou

AU - Warren, Mitchell

AU - Cooper, David

AU - Kaleebu, Pontiano

AU - Macklin, Ruth

AU - Tangwa, Godfrey

PY - 2007/2

Y1 - 2007/2

N2 - This report summarizes the discussions and recommendations from a consultation held in New York City, USA (31 January-2 February 2006) organized by the joint World Health Organization-United Nations Programme on HIV/AIDS HIV Vaccine Initiative and the International AIDS Vaccine Initiative. The consultation discussed issues related to the design and implementation of phase IIB 'test of concept' trials (phase IIB-TOC), also referred to as 'proof of concept' trials, in evaluating candidate HIV vaccines and their implications for future approval and licensure. The results of a single phase IIB-TOC trial would not be expected to provide sufficient evidence of safety or efficacy required for licensure. In many instances, phase IIB-TOC trials may be undertaken relatively early in development, before manufacturing processes and capacity are developed sufficiently to distribute the vaccine on a large scale. However, experts at this meeting considered the pressure that could arise, particularly in regions hardest hit by AIDS, if a phase IIB-TOC trial showed high levels of efficacy. The group largely agreed that full-scale phase III trials would still be necessary to demonstrate that the vaccine candidate was safe and effective, but emphasized that governments and organizations conducting trials should consider these issues in advance. The recommendations from this meeting should be helpful for all organizations involved in HIV vaccine trials, in particular for the national regulatory authorities in assessing the utility of phase IIB-TOC trials in the overall HIV vaccine research and development process.

AB - This report summarizes the discussions and recommendations from a consultation held in New York City, USA (31 January-2 February 2006) organized by the joint World Health Organization-United Nations Programme on HIV/AIDS HIV Vaccine Initiative and the International AIDS Vaccine Initiative. The consultation discussed issues related to the design and implementation of phase IIB 'test of concept' trials (phase IIB-TOC), also referred to as 'proof of concept' trials, in evaluating candidate HIV vaccines and their implications for future approval and licensure. The results of a single phase IIB-TOC trial would not be expected to provide sufficient evidence of safety or efficacy required for licensure. In many instances, phase IIB-TOC trials may be undertaken relatively early in development, before manufacturing processes and capacity are developed sufficiently to distribute the vaccine on a large scale. However, experts at this meeting considered the pressure that could arise, particularly in regions hardest hit by AIDS, if a phase IIB-TOC trial showed high levels of efficacy. The group largely agreed that full-scale phase III trials would still be necessary to demonstrate that the vaccine candidate was safe and effective, but emphasized that governments and organizations conducting trials should consider these issues in advance. The recommendations from this meeting should be helpful for all organizations involved in HIV vaccine trials, in particular for the national regulatory authorities in assessing the utility of phase IIB-TOC trials in the overall HIV vaccine research and development process.

KW - Clinical trial design

KW - HIV vaccines

KW - Phase IIB trials

KW - Proof of concept trials

KW - Test of concept trials

KW - Vaccine efficacy

UR - http://www.scopus.com/inward/record.url?scp=33847016909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847016909&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328011a0c9

DO - 10.1097/QAD.0b013e328011a0c9

M3 - Article

C2 - 17301582

AN - SCOPUS:33847016909

VL - 21

SP - 539

EP - 546

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -